CollPlant Biotechnologies (CLGN) and Stratasys Ltd. (SSYS) have announced the initiation of a pre-clinical study for 3D printed regenerative breast implants. The study will utilize 200cc commercial-sized implants printed on a Stratasys Origin 3D printer, focusing on their potential to grow natural breast tissue and biodegrade completely over time. This collaboration marks a significant step forward in the companies’ efforts to revolutionize breast reconstruction and augmentation procedures using regenerative medicine instead of traditional implants.
The implants, consisting of CollPlant’s rhCollagen-based bioinks, are being tested in the pre-clinical study. Stratasys has modified its Origin printer specifically for printing these regenerative implants, following their initial collaboration announcement in April 2023. CollPlant anticipates initial results from the study in the first half of 2025.
The primary objective of the study is to evaluate the implants’ ability to stimulate the formation of native breast tissue while eventually degrading entirely. This innovative approach could potentially revolutionize the breast implant market, offering a groundbreaking alternative for reconstructive and cosmetic procedures.
The global breast implant market is estimated to be worth $3 billion, with breast reconstruction and augmentation procedures being the second most common plastic surgery procedures worldwide. Currently, the most common procedures utilize synthetic silicone implants, which are artificial substitutes for natural regenerated tissue and carry the risk of complications. CollPlant’s regenerative breast implants, designed to regenerate an individual’s natural breast tissue without triggering an immune reaction, could offer a significant advancement in this field.
While CollPlant specializes in regenerative and aesthetic medicine, developing innovative technologies based on its rhCollagen for tissue regeneration and organ production, Stratasys is a leader in polymer 3D printing solutions. This collaboration focuses on developing a bioprinting solution for CollPlant’s breast implants and streamlining the implant construction process.
The potential impact of this study and the collaboration between CollPlant and Stratasys could be substantial. Their innovative approach to breast implants could significantly change the landscape of breast reconstruction and augmentation procedures, offering patients a safe and natural alternative to existing options. Initial results are anticipated in the first half of 2025, making this a project worth watching closely in the medical technology space.
